



TearCare[®]
Promise



We Care So Much, We Promise Results.

We care enough about the success of your treatment to put a guarantee behind the TearCare[®] System, a TearCare[®] Promise.



Dry eye disease is a chronic and progressive disease, but we believe TearCare[®] can assist in improving your dry eye disease.


We care so much about your treatment success, and we are so confident we can help your eye care provider help you that we are willing to guarantee your success with TearCare.



Although dry eye can be a real challenge to treat¹, we are confident that TearCare can meaningfully improve the most bothersome parts of dry eye!

Your doctor will measure your Tear Break Up Time (TBUT) as a key sign of tear film wellness^{2,3}. Your eye care provider will take this measurement before your TearCare procedure. As part of the TearCare Promise we would expect the TBUT to improve by at least 50%.

Your doctor will also administer the SPEED* dry eye questionnaire. The questionnaire looks at numerous categories to better understand how you may be doing symptomatically after treatment. As part of the TearCare Promise we would expect SPEED scores to improve by at least 50%.





Based on years of experience successfully treating patients with dry eye disease utilizing the TearCare System¹, we are confident the TearCare[®] System can improve elements of your dry eye within 4 to 6 weeks.

Should TBUT not improve by 50% AND SPEED* not improve by 50% we will provide your doctor, at no charge to you, a second set of disposable SmartLids™ to provide a retreatment[#].

If after retreatment both TBUT AND SPEED* scores still did not improve by 50%, Sight Sciences will refund you the price of the treatment[#].



**#Please scan the QR for
complete Terms and Conditions**

* SPEED is a trademark of another company

¹ Gupta PK, et al TearCare for the Treatment of Meibomian Gland Dysfunction in Adult Patients With Dry Eye Disease: A Masked Randomized Controlled Trial. *Cornea*. 2022 Apr 1;41(4):417-426.

² McMonnies, Why the symptoms and objective signs of dry eye disease may not correlate, *Journal of Optometry*, Volume 14, Issue 1, 2021

³ Tsubota K. Short Tear Film Breakup Time-Type Dry Eye. *Invest Ophthalmol Vis Sci*. 2018 Nov 1;59

TearCare[®] System – Patient Important Safety Information.
Indications for Use: The TearCare[®] System is intended for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands. Potential adverse events associated with the use of the TearCare[®] system include: swelling, redness or discomfort of eyelids, allergic reaction to medical adhesive, temporary visual disturbance such as blurry vision, foreign body sensation, stye, or blocked oil glands, temporary worsening of dryness in the eye. Please talk to your doctor for complete risk information, and to discuss whether the TearCare[®] system is right for you.

TearCare, Sight Sciences, and the Sight Sciences logo are registered trademarks of Sight Sciences, Inc.